Targeting human C-type lectin-like molecule-1 (CLL1) with a bispecific antibody for immunotherapy of acute myeloid leukemia.

Targeting human C-type lectin-like molecule-1 (CLL1) with a bispecific antibody for immunotherapy of acute myeloid leukemia.
复制标题

DOI:
10.1002/anie.201405353
复制
发表时间:
2014-09-08
影响因子:
16.6
通讯作者:
Schultz, Peter G.
Schultz, Peter G.
中科院分区:
化学1区
文献类型:
--
作者:
Lu, Hua;Zhou, Quan;Deshmukh, Vishal;Phull, Hardeep;Ma, Jennifer;Tardif, Virginie;Naik, Rahul R.;Bouvard, Claire;Zhang, Yong;Choi, Seihyun;Lawson, Brian R.;Zhu, Shoutian;Kim, Chan Hyuk;Schultz, Peter G.

文献摘要

参考文献

被引文献

相似文献

急性髓性白血病(AML)是最常见的急性成人白血病和第二常见的儿童白血病,其预后仍然很差。人C型凝集素样分子-1(CLL 1)是最近发现的一种髓系限制性细胞表面标志物,在超过90%的AML患者髓系母细胞和白血病干细胞中过表达。在这里,我们描述了一种新的双特异性抗体,α CLL 1-α CD 3,使用基因编码的非天然氨基酸,对乙酰苯丙氨酸的合成。所得α CLL 1-α CD 3将细胞毒性T细胞募集至CLL 1阳性细胞,并在体外对几种人AML细胞系和原代AML患者源性细胞显示出强效和选择性细胞毒性。此外,α CLL 1-α CD 3治疗完全消除了U937 AML细胞系异种移植模型中已建立的肿瘤。这些结果验证了CLL 1作为AML特异性抗原用于产生AML的新型免疫抑制剂的临床潜力。
Acute myeloid leukemia (AML), the most common acute adult leukemia and the second most common pediatric leukemia, still has a poor prognosis. Human C-type lectin-like molecule-1 (CLL1) is a recently identified myeloid lineage restricted cell surface marker, which is overexpressed in over 90% of AML patient myeloid blasts and in leukemic stem cells. Here, we describe the synthesis of a novel bispecific antibody, αCLL1-αCD3, using the genetically encoded unnatural amino acid, p-acetylphenylalanine. The resulting αCLL1-αCD3 recruits cytotoxic T cells to CLL1 positive cells, and demonstrates potent and selective cytotoxicity against several human AML cell lines and primary AML patient-derived cells in vitro. Moreover, αCLL1-αCD3 treatment completely eliminates established tumors in an U937 AML cell line xenograft model. These results validate the clinical potential of CLL1 as an AML specific antigen for the generation of a novel immunotherapeutic for AML.
DOI: 10.1038/sj.leu.2402803
发表时间: 2003-02-01
期刊: LEUKEMIA
影响因子: 11.4
作者:
Feldman, E;Kalaycio, M;Wedel, N
通讯作者: Wedel, N
CD47是人类急性髓样白血病干细胞的不良预后因素和治疗抗体靶标。
DOI: 10.1016/j.cell.2009.05.045
发表时间: 2009-07-23
期刊: Cell
影响因子: 64.5
作者:
Majeti R;Chao MP;Alizadeh AA;Pang WW;Jaiswal S;Gibbs KD Jr;van Rooijen N;Weissman IL
通讯作者: Weissman IL
DOI: 10.1158/0008-5472.can-07-2182
发表时间: 2008-01-01
期刊: CANCER RESEARCH
影响因子: 11.2
作者:
Amann, Maria;Brischwein, Klaus;Schlereth, Bernd
通讯作者: Schlereth, Bernd
DOI: 10.1016/j.molimm.2005.07.034
发表时间: 2006-03-01
影响因子: 3.6
作者:
Brischwein, K;Schlereth, B;Baeuerle, PA
通讯作者: Baeuerle, PA
DOI: 10.1021/ja303904e
发表时间: 2012-06-20
影响因子: 15
作者:
Kim CH;Axup JY;Dubrovska A;Kazane SA;Hutchins BA;Wold ED;Smider VV;Schultz PG
通讯作者: Schultz PG